Файл: Утверждаю заместитель Министра здравоохранения Российской Федерации А. Н. Плутницкий временные методические рекомендации профилактика, диагностика и лечение новой коронавирусной инфекции (covid19) 3 Версия 16 (18. 08. 2022)оглавление.pdf

153
Версия 16 (18.08.2022)
и лицах с признаками пневмонии. Сведения направляются в соответствии с порядком, изложенным в инструкции по внесению сведений в информационный ресурс, размещенной по адресу http://portal.egisz.rosminzdrav.ru/materials/3557
, в установленные сроки:
В течение 2 ч с момента установления диагноза новой коронавирусной инфекции
(COVID-19) или госпитализации пациента с признаками пневмонии;
В течение 2 ч с момента получения результатов лабораторных исследований.
При внесении информации о пациенте необходимо указать:
а) Дату появления клинических симптомов; б) Диагноз (указывается код по МКБ-10); в) Дату постановки диагноза; г) Наличие сопутствующих (коморбидных) заболеваний:
Хронических заболеваний бронхолегочной системы;
Хронических заболеваний сердечно-сосудистой системы;
Хронических заболеваний эндокринной системы;
Онкологических заболеваний;
ВИЧ-инфекции; туберкулеза; иных заболеваний. д) Наличие беременности; е) Сведения о вакцинации (грипп и пневмококковая инфекция (при наличии).
В ежедневном режиме необходимо обеспечить обновление медицинской информации о пациенте: ж) Сведения о проводимом лечении:
Противовирусное лечение;
Респираторная поддержка (ИВЛ, ЭКМО); з) Уровень сатурации кислорода в крови; и) Тяжесть течения заболевания.
В случае смерти пациента
а) В течение суток заполняется раздел «Заключительный клинический диагноз»:
Основное заболевание;
Коморбидные, конкурирующие, сочетанные и фоновые заболевания;
Осложнения (основного заболевания, коморбидных заболеваний) – при их наличии;
Сопутствующие заболевания (при наличии). б) В течение суток с момента проведения вскрытия заполняется раздел
«Предварительный патологоанатомический
(судебно-медицинский) диагноз» по результатам первого этапа патологоанатомического или судебно-медицинского исследования:

154
Версия 16 (18.08.2022)
Основное заболевание;
Коморбидные, конкурирующие, сочетанные и фоновые заболевания;
Осложнения (основного заболевания, коморбидных заболеваний) – при их наличии;
Сопутствующие заболевания (при наличии);
Скан-копия первой части протокола патологоанатомического вскрытия или выписка из результатов наружного и внутреннего судебно-медицинского исследования, содержащая патологические изменения, которые легли в основу постановки судебно- медицинского диагноза. в) «Медицинское свидетельство о смерти»:

155
Версия 16 (18.08.2022)
Использованные источники
1.
Abramowicz J.S., Basseal J. Заявление о позиции WFUMB: как безопасно проводить ультразвуковое исследование и обеззараживать ультразвуковое оборудование в условиях
COVID-19 // Ультразвуковая и функциональная диагностика. 2020. № 1. С. 12–23. Doi:
10.24835/1607-0771-2020-1-12-23.
Опубликовано до печати.
Режим доступа:
// http://www.rasudm.org/files/WFUMB-Position-Statement-COVID.pdf, свободный. Загл. с экрана.
16.04.2020.
2.
Ai T. et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases [published online ahead of print, 2020 Feb 26] // Radiology. 2020.
200642. Doi: 10.1148/radiol.2020200642.
3.
Al-Tawfiq J. A., Memish Z. A. Update on therapeutic options for Middle East Respiratory Syndrome
Coronavirus (MERS-CoV) // Expert review of anti-infective therapy. 2017. 15. № 3. С. 269–275.
4.
Alserehi H. et al. Impact of Middle East respiratory syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome // BMC Infect Dis. 2016. №16, p. 105.
5.
Assiri A. et al. Middle East respiratory syndrome coronavirus infection during pregnancy: a report of 5 cases from Saudi Arabia // Clin Infect Dis. 2016. № 63. pp. 951-953.
6.
Baig A.M. et al.Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus
Interaction, and
Proposed
Neurotropic
Mechanisms.
ACS
Chem.
Neurosci.
2020. doi:10.1021/acschemneuro.0c00122.
7.
Bassetti M. The Novel Chinese Coronavirus (2019
‐nCoV) Infections: challenges for fighting the storm https://doi.org/10.1111/eci.13209. URL: https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.13209 8.
Behzadi M.A., Leyva-Grado V.H. Overview of Current Therapeutics and Novel Candidates Against
Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections //
Frontiers in microbiology. 2019. № 10. p. 1327.
9.
Beigel J.H. et al. ACTT-1 Study Group Members. Remdesivir for the Treatment of COVID-19 - Final
Report. N Engl J Med. 2020 Oct 8: NEJMoa2007764. doi: 10.1056/NEJMoa2007764.
10.
Bein T et al. S2e guideline: positioning and early mobilisation in prophylaxis or therapy of pulmonary disorders Revision. Anaesthesist. 2015;64(September):1-26. doi:10.1007/s00101-015-0071-1.
11.
Beloncle F, Mercat A Approaches and Techniques to Avoid Development or Progression of Acute
Respiratory Distress Syndrome Review Curr Opin Crit Care 2018 Feb;24(1):10-15. doi:
10.1097/MCC.0000000000000477.
12.
Benefits, Open questions and Challenges of the use of Ultrasound in the COVID-19 pandemic era. The views of a panel of worldwide international experts [published online ahead of print, 2020 Apr 15] //
Ultraschall Med. 2020;10.1055/a-1149-9872. Doi: 10.1055/a-1149-9872.
13.
Bernheim A. et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Radiology. 2020:200463. doi:10.1148/radiol.2020200463.
14.
Busani S, Dall’Ara L, Tonelli R, et al. Surfactant replacement might help recovery of low-compliance lung in severe COVID-19 pneumonia. Ther Adv Respir Dis 2020, 14: 1–6 DOI:
10.1177/1753466620951043.
15.
Canada.ca. 2019 novel coronavirus: Symptoms and treatment The official website of the Government of
Canada.
URL: https://www.canada.ca/en/public-health/services/diseases/2019-novel- coronavirusinfection/symptoms.html
16.
Carmeli Y. et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa.
Arch Intern Med. 1999 May 24;159(10):1127-32.
17.
CDC. 2019 Novel Coronavirus. URL: https://www.cdc.gov/coronavirus/2019-ncov/index.html
18.
Ceribelli A, et al. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J Autoimmun. 2020 May; 109:102442. doi: 10.1016/j.jaut.2020.102442.
19.
Chaolin H. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China?
Lancet 2020; 395: 497–506 Published Online January 24, 2020. https://doi.org/10.1016/ S0140-
6736(20)30183-5 20.
Chaomin Wu et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in
Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. Published online March 13, 2020. doi:10.1001/jamainternmed.2020.099.
21.
Chen N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study // Lancet. 2020. doi: 10.1016/S0140-6736(20)30211-7.
22.
China CDC. Diagnosis and treatment protocolfor COVID-19 patients (trial version 7, revised).
23.
Chong Y.P. et al. Antiviral Treatment Guidelines for Middle East Respiratory Syndrome // Infection & chemotherapy. 2015. 47. № 3. pp. 212–222.
24.
Chung M. et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV) // Radiology. 2020. V.
295. No. 1. P. 202–207. Doi: 10.1148/radiol.2020200230.
25.
Cinatl J. et al. Treatment of SARS with human interferons // Lancet. 2003. 362. № 9380. pp. 293–294.

156
Версия 16 (18.08.2022)
26.
Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected: Interim Guidance. Updated 2 July 2015.
WHO/MERS/Clinical/15.1.
27.
Colson, P., Rolain, J. M., Lagier, J. C., Brouqui, P., & Raoult, D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 International Journal of Antimicrobial Agents 2020.
28.
Commonwealth of Australia | Department of Health. Novel coronavirus (2019-nCoV) URL: https://www.health.gov.au/health-topics/novel-coronavirus-2019-ncov
29.
Copin R, et al. In vitro and in vivo preclinical studies predict REGEN-COV protection against emergence of viral escape in humans. bioRxiv 2021.03.10.434834.
30.
Corman V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
//Eurosurveillance. 2020. (3)25. doi: 10.2807/1560-7917.ES.
31.
Coronavirus.
URL
: https://multimedia.scmp.com/widgets/china/wuhanvirus/?fbclid=IwAR2hDHzpZEh5Nj360i2O%201ES
78rXRFymAaFaUK6ZG4m0UTCV1xozulxX1jio
COVID Care Protocol.
Last Updated 05-11-2020 3:15 p.m.
https://www.evms.edu/COVID-19/COVID_care_for_clinicians/#COVIDcare
32.
Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020). A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care .
33.
COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone diseases.
NICE guideline, published 3 april 2020. URL: www.nice.org./uk/guidancr/ng167 34.
COVID-19: guidance for rheumatologists.
British
Society of
Rheumatology.
URL: htpps//www.rheumatology.org.uk
35.
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.
National Institutes of Health. Available at https://www.COVID19treatmentguidelines.nih.gov/
36.
Critical Care COVID-19 Management Protocol (updated 4-15-2020).
37.
David C et al. Postacute Care Preparedness for COVID-19Thinking Ahead Author Affiliations Article
Information JAMA. Published online March 25, 2020. doi:10.1001/jama.2020.4686.
38.
Dayer M.R. et al. Lopinavir; A Potent Drug against Coronavirus Infection: Insight from Molecular
Docking Study // Arch Clin Infect Dis. 2017 ; 12(4):e13823. doi: 10.5812/archcid.13823.
39.
Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 Mar 12:105938. doi:
10.1016/j.ijantimicag.2020.105938.
40.
Dyall J. et al. Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current
Therapeutic Options and Potential Targets for Novel Therapies // Drugs. 2017. 77. № 18. С. 1935–1966.
41.
Eggmann S et al. Physiological effects and safety of an early, combined endurance and resistance training in mechanically ventilated, critically ill patients.
Physiotherapy.
2015;101:e344-e345. doi:10.1016/j.physio.2015.03.553 42.
ESMO guidelines Cancer patients’ management during the COVID-19 pandemic. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic
43.
European Commission. Novel coronavirus 2019-nCoV URL: https://ec.europa.eu/health/coronavirus_en
44.
Fact sheet for health care providers emergency use authorization (EUA) of casirivimab and imdevimab.
URL: https://www.fda.gov/media/143892/download
45.
Fan HH. et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a
2019-novel coronavirus (2019-nCoV) related coronavirus model. Chin Med J (Engl). 2020 Mar 6. doi:
10.1097/CM9.0000000000000797.
46.
Fang Y. et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR [published online ahead of print, 2020 Feb 19] // Radiology. 2020. 200432. Doi: 10.1148/radiol.2020200432.
47.
Favipiravir versus
Arbidol for
COVID-19:
A
Randomized
Clinical
Trial. https://doi.org/10.1101/2020.03.17.20037432.
48.
FDA.
Novel coronavirus
(2019-nCoV)
URL: https://www.fda.gov/emergency-preparedness- andresponse/mcm-issues/novel-coronavirus-2019-ncov
49.
Federal
Ministry of
Health.
Current information on the coronavirus.
URL: https://www.bundesgesundheitsministerium.de/en/en/press/2020/coronavirus.html
50.
Fossat G et al. Effect of in-bed leg cycling and electrical stimulation of the quadriceps on global muscle strength in critically ill adults: A Randomized Clinical Trial. JAMA. 2018; 320 (4): 368–378.
51.
Franquet T. Imaging of pulmonary viral pneumonia // Radiology. 2011. V. 260. No. 1. P. 18–39. Doi:
10.1148/radiol.11092149.
52.
Furuta Y, et al. : Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad
Ser B Phys Biol Sci. 2017;93(7):449-463. doi: 10.2183/pjab.93.027.
53.
Gao, J., Tian, Z., & Yang, X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends 2020.

157
Версия 16 (18.08.2022)
54.
Gautret F., Lagier J-C., Parola P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID19: results of an openlabel non-randomized clinical trial. International Journal of Antimicrobial Agents. In
Press 17 March 2020 –DOI : 10.1016/j.ijantimicag.2020.105949.
55.
Gorbalenya A.E.et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses
– a statement of the Coronavirus Study Group, 2020. doi: https://doi.org/10.1101/2020.02.07.937862.
56.
Guarner F., e.a. World Gastroenterology Organisation Global Guidelines. Probiotics and prebiotics.
February
2017.
Available at: http://www.worldgastroenterology.org/guidelines/global- guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english
57.
Halyabar O. et al.
Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome,
Pediatric
Rheumatology. URL: https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-019-0309-6 58.
Hart B.J. et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays // The Journal of general virology. 2014. 95. Pt 3. С. 571–577.
59.
Heching M, Lev S, Shitenberg D, Dicker D, Kramer MR, Surfactant for Treatment of ARDS in COVID-
19 Patient. Chest 2021: doi: https://doi.org/10.1016/j.chest.2021.01.028 60.
Henderson L.A. et al. On the Alert for Cytokine Storm: Immunopathology in COVID
‐19 Arthritis &
Rheumatology Vol. 0, No. 0, Month 2020, pp 1–5. DOI: 10.1002/art.41285.
61.
Henk J Stam et al. COVID-19 and Post Intensive Care Syndrome: A Call for Action. J Rehabil Med 2020
Apr 15;52(4):jrm00044. doi: 10.2340/16501977-2677.
62. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=4a3c02bc-a256-48f2-90a8-
14b48b7d197c&t
=
63. https://www.vmeda.org/wp-content/uploads/2020/03/koronavirus-metod-rekomendaczii.pdf
64.
Huang C. et al. Cinical features of patients infected with 2019 novel coronavirus in Wuhan, China //
Lancet. 2020 doi: 10.1016/S0140-6736(20)30183-5. [Epub ahead of print].
65.
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with
COVID-19
. Published by IDSA.
URL:https://www.idsociety.org/practice-guideline/COVID-19- guideline-treatment-and-management/
, [COVID-19 Guideline, Part 1: Treatment and Management].
66.
Inui S. et al. Chest CT Findings in Cases from the Cruise Ship “Diamond Princess” with Coronavirus
Disease
2019
(COVID-19).
Radiology:
Cardiothoracic
Imaging.
2020;2:e200110. doi:10.1148/ryct.2020200110.
67.
Jeong S.Y. et al. MERS-CoV Infection in a Pregnant Woman in Korea. J Korean Med Sci. 2017
Oct;32(10):1717-1720. doi: 10.3346/jkms.2017.32.10.1717.
68.
Jesú V. et al. Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress
Syndrome Caused by Coronavirus Disease 2019. ritical Care Explorations: April 2020 - Volume 2 - Issue
4 - p e0111 doi: 10.1097/CCE.0000000000000111.
69.
Ji W. et al. Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross
‐species transmission from snake to human //Journal of Medical Virology. – 2020.
70.
Julie K. Silver: Prehabilitation could save lives in a pandemic. March 19, 2020.
71.
Junqiang L. et al. CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia https://doi.org/10.1148/radiol.2020200236. URL: https://pubs.rsna.org/doi/10.1148/radiol.2020200236 72.
Karatzanos E et al. Electrical muscle stimulation: An effective form of exercise and early mobilization to preserve muscle strength in critically ill patients. Crit Care Res Pract. 2012; 2012: 432752.
73.
Kimberly Showalter, et al. Advice on Treating Rheumatic Diseases From a COVID-19 Epicenter -
Medscape - May 11, 2020.
74.
Kligerman S.J., Franks T.J., Galvin J.R. From the radiologic pathology archives: organization and fibrosis as a response to lung injury in diffuse alveolar damage, organizing pneumonia, and acute fibrinous and organizing pneumonia // Radiographics. 2013. V. 33. No. 7. P. 1951–1975. Doi: 10.1148/rg.337130057.
75.
Kress, J.P. and J.B. Hall, ICU-acquired weakness and recovery from critical illness. N Engl J Med, 2014.
370(17): p. 1626-35.
76.
Kuderer N.M. Chouein T.K., Shah D.P. et al. Clinical impact of COVID-19 jn patients with cancer
(CCC19): A COHORT STUDY. Lncet 2020; S0140-6736(20)31187-9. Doi; 10.1016.S0140-
6736(20)311197-9.
77.
Kumar B. et al. A Personalized Diagnostic and Treatment Approach for Macrophage Activation
Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Adults. Journal of Clinical
Immunology, volume 37, pages 638–643(2017). URL: https://link.springer.com/article/10.1007/s10875-
017-0439-x
78.
Le Chang et al. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfusion Medicine
Reviews 2020. doi:10.1016/j.tmrv.2020.02.003.
79.
Lee Kyung Soo. Pneumonia Associated with 2019 Novel Coronavirus: Can Computed Tomographic
Findings Help Predict the Prognosis of the Disease? Korean Journal of Radiology(2020), 21 (3):257.

158
Версия 16 (18.08.2022)
80.
Li Q et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia N
Engl J Med. 2020 Jan 29. doi: 10.1056/NEJMoa2001316.
81.
Li X et al. Potential of large 'first generation' human-to-human transmission of 2019-nCoV. J Med Virol.
2020 Jan 30. doi: 10.1002/jmv.25693. [Epub ahead of print]
82.
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020 Jan 28. doi: 10.5582/bst.2020.01020. [Epub ahead of print]
83.
Lu W., Zhang S., Chen B. et al. A Clinical Study of Noninvasive Assessment of Lung Lesions in Patients with Coronavirus Disease-19 (COVID-19) by Bedside Ultrasound [published online ahead of print, 2020
Apr 15] // Ultraschall Med. 2020;10.1055/a-1154-8795. Doi: 10.1055/a-1154-8795.
84.
Ludvigsson JF. Systematic review of COVID
‐19 in children show milder cases and a better prognosis than adults. URL: https://doi.org/10.1111/apa.15270 85.
Lupia T., Scabini S., Pinna S.M., Di Perri G., De Rosa F.G., Corcione S. 2019 novel coronavirus (2019- nCoV) outbreak: A new challenge, Journal of Global Antimicrobial Resistance 21 (2020) 22–27.
86.
Ly-Mee Yu et al. Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the
PRINCIPLE trial.
2021.
URL: https://www.medrxiv.org/content/10.1101/2021.04.10.21254672v1 87.
M.Ackermann, S. Verleden, M.Kuehnel, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and
Angiogenesis in COVID-19. DOI: 10.1056/NEJMoa2015432.
88.
Mandell L.A. et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults //Clinical infectious diseases.
– 2007. – Т. 44. – №. Supplement_2. – pp. S27-S72.
89.
Mao L. et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: A retrospective case series study; 2020. doi: https://doi.org/10.1101/2020.02.22.20026500.
90.
Maude S.L. et al. Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging
Therapies Cancer J. 2014 Mar-Apr; 20(2): 119–122. doi: 10.1097/PPO.0000000000000035.
91.
Medrinal C et al. Comparison of exercise intensity during four early rehabilitation techniques in sedated and ventilated patients in ICU: A randomised cross-over trial. Crit Care. 2018; 22 (1):110.
92.
Mehta P, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020
Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
93.
Michele Vitacca et al. Joint statement on the role of respiratory rehabilitation in the COVID-19 crisis: the
Italian position paper Version - March 08, 2020. Graphics and publishing AIPO Ricerche Ed. – Milano.
URL: edizioni@aiporicerche.it
94.
Mikuls TR, et al. American College of Rheumatology guidance for the management of adult patients with rheumatic disease during the
COVID-19 pandemic.
Arthritis
Rheumatol. doi: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41301.
95.
Ministère des
Solidarités et de la
Santé
Coronavirus: questions-réponses.
URL: https://solidaritessante.gouv.fr/soins-et-maladies/maladies/maladies- infectieuses/coronavirus/coronavirus-questionsreponses
96.
Moores L.K., Tritschler T., Brosnahan S., et al. Prevention, Diagnosis, and Treatment of VTE in Patients
With
COVID-19.
CHEST
Guideline and
Expert
Panel
Report.
Chest
2020;
DOI:
10.1016/j.chest.2020.05.559.
97.
Mo Y., Fisher D.A. Review of treatment modalities for Middle East Respiratory Syndrome // The Journal of antimicrobial chemotherapy. 2016. 71. № 12. pp. 3340–3350.
98.
Momattin H. et al. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)- possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis. 2013 Oct;17(10):e7928.
99.
MR Mehra, et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of
COVID-19: a multinational registry analysis,Lancet, 2020.
100. National Health Commission of the People's Republic of China. URL: http://en.nhc.gov.cn
101. Netland J. Severe Acute Respiratory Syndrome Coronavirus Infection Causes Neuronal Death in the
Absence of Encephalitis in Mice Transgenic for Human ACE2. J Virol. 2008;82:7264–75. doi:10.1128/JVI.00737-08.
102. NHS. Coronavirus (2019-nCoV). URL: https://www.nhs.uk/conditions/wuhan-novel-coronavirus/
103. Omrani A.S. et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study //The Lancet Infectious Diseases. 2014. Т. 14. №. 11. pp. 1090-1095.
104. Outbreak of acute respiratory syndrome associated with a novel coronavirus, China: first local transmission in the
EU/EEA
− third update.
URL: https://www.ecdc.europa.eu/sites/default/files/documents/novel-coronavirus-risk-assessment-china-
31january-2020_0.pdf